<DOC>
	<DOC>NCT02565914</DOC>
	<brief_summary>This is a Phase 3, multicenter, open-label, rollover study in subjects with CF who are homozygous or heterozygous for the F508del-CFTR mutation and who participated in Studies 103 (NCT02070744), 106 (NCT02347657), 107 (NCT02516410), 108 (NCT02392234), 109 (NCT02412111), and 111 (NCT02508207). The study is designed to evaluate the safety and efficacy of long term treatment of VX-661 in combination with ivacaftor. This study consists of a Treatment Cohort and an Observational Cohort. The Treatment Cohort and the Observational Cohort will be open to enrollment in parallel.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Subjects entering the Treatment Cohort must meet all of the following criteria: Elect to enroll in the Treatment Cohort Completed study drug Treatment Period in a parent study (Studies 103 [Placebo Controlled Phase or Open Label Extension Phase], 106, 107, 108, or 109) or study drug treatment and the Safety Follow up Visit for subjects from Study 111 Willing to remain on a stable CF regimen through the Safety Followup Visit. Subjects entering the Observational Cohort must meet the following criteria: &lt;18 years of age (age on the date of informed consent/assent in the parent study) Completed study drug Treatment Period in a parent study or study drug treatment and the Safety Follow up Visit for subjects from Study 111, but do not elect to enroll in the Study 110 Treatment Cohort; or Received at least 4 weeks of study drug treatment and completed visits up to the last scheduled visit of the Treatment Period of a parent study (and the Safety Follow up Visit for subjects from Study 111), but do not meet eligibility criteria for enrollment into the Treatment Cohort History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the subject. Pregnant and nursing females. Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements. History of drug intolerance in the parent study that would pose an additional risk to the subject. Participation in an investigational drug trial (including studies investigating VX 661/ivacaftor or lumacaftor/ivacaftor) other than parent studies or 111 (NCT02508207) or use of a commercially available CFTR modulator.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>